Truist has lowered its price target for Boston Scientific Corporation (BSX) to $90 from $92, while maintaining a Buy rating. This adjustment reflects multiple contraction for the MedTech group, though Truist anticipates the stock's valuation to rebound to at least 23-times its one-year forward earnings. RBC Capital also reduced its price target for BSX to $105 from $115, maintaining an Outperform rating, both updates coming ahead of fiscal Q1 results for MedTech companies.

CICC has initiated coverage of Pfizer Inc. (PFE) with an Outperform rating and a $33 price target. This follows Pfizer's announcement of positive topline results from its Phase 3 VALOR clinical trial for an investigational Lyme disease vaccine, showing over 70% efficacy with no safety concerns. The company plans to submit regulatory applications for the vaccine, highlighting its potential in an area with no currently available vaccines.

Ulta Beauty Inc (ULTA) shares surged 3.4% to $572.24, making it 3.0% overvalued according to its GF Value of $555.55. Despite this, the company boasts an impressive GF Score of 99/100, driven by perfect scores in Profitability and Growth. However, investors are cautioned by recent insider selling activity, with $0.2 million in shares sold over the last three months and no buying reported.

Arch Capital Group (ACGL) has increased its share repurchase authorization by $3 billion, signaling confidence in its financial health and commitment to shareholder returns. The company boasts a strong GF Score of 92/100 and an attractive P/E ratio of 8.39, suggesting potential undervaluation. However, recent insider selling of $7.3 million warrants investor attention.

Biogen Inc (BIIB) shares surged 3.4% to $183.34, leading to a "fairly valued" verdict from GF Value™ despite being 8.6% undervalued compared to the $200.50 estimate. The company's GF Score™ of 72/100 indicates solid potential, primarily driven by its perfect 10/10 Valuation score, though growth prospects are limited (2/10 G.F Rating). Insider selling activity of $0.7 million in the last three months suggests caution for potential investors.

Pharvaris N.V.'s Chief Medical Officer, Lu Peng, reported a routine tax-related share withholding event. On April 16, 2026, 226 common shares were disposed of at $28.78 per share to satisfy tax obligations from vested restricted stock units. After this transaction, Lu Peng directly holds 66,083 common shares.

Nucor Corp (NUE) shares surged 3.3% to $202.26, despite being classified as "Modestly Overvalued" by GuruFocus's GF Value™ at $158.85. The company boasts a high GF Score™ of 94/100, driven by strong profitability, growth, and a perfect momentum rank, indicating potential for long-term returns. However, the overvaluation and recent insider selling suggest caution for new investors.

NRG Energy Inc (NRG) shares dropped 6.3% to $157.18, yet GuruFocus's GF Value™ suggests the stock is still significantly overvalued by 52.1%, with a fair value of $103.32. This assessment is supported by a high P/E ratio of 39.7x, significantly above its historical median, and substantial insider selling totaling $5,291.2 million with no reported buying activity. While NRG has a strong GF Score™ of 82/100 for growth and momentum, its low valuation score of 3/10 raises concerns for investors.

Dow Inc (DOW) shares rose 3.3% to $36.77, trading below its GF Value™ of $40.26, suggesting it is undervalued by approximately 8.7%. Despite this, the stock's forward P/E ratio of 36.3x is higher than its 5-year median, and its momentum rank is low. The GF Score™ of 63/100 rates DOW as "Above Average," primarily due to its strong valuation score.

Jefferies analyst Kaumil Gajrawala has lowered the price target for Colgate-Palmolive Company (NYSE: CL) to $88.00 from $91.00. The article is a premium-only piece, requiring a subscription to StreetInsider.com Premium for full access.